摘要
溃疡性结肠炎(UC)是一种多因素导致的慢性炎症性肠病,其病因和发病机制尚不完全清楚。托法替尼是一种小分子物质,主要通过抑制Janus激酶(JAK)治疗UC,可通过口服快速吸收。该药已被美国FDA及欧洲药品管理局批准用于治疗中重度UC,且国外已开展较多托法替尼治疗UC的临床研究,而其在我国尚未见有用于UC的相关报道。本文主要从托法替尼治疗UC的作用机制、临床应用、安全性等方面总结其相关研究进展。结果表明,托法替尼主要通过抑制JAK和促炎因子的表达、调节过表达的信号转导及转录激活因子信号、修复肠黏膜屏障等作用治疗UC。托法替尼在临床显示出较好的疗效,但安全性研究显示其所带来的带状疱疹、血栓形成等风险不容忽视,妊娠期、儿童、青少年、老年患者应慎用该药。由于目前暂未见其在我国用于UC,未来需进一步研究托法替尼在我国UC患者中的疗效和安全性。
Ulcerative colitis(UC)is a chronic inflammatory bowel disease caused by multiple factors,and its etiology and pathogenesis remain unclear.Tofacitinib,a small molecule rapidly absorbed by oral administration,treats UC primarily by inhibiting Janus kinase(JAK).Tofacitinib has been approved by the FDA and the European Medicines Agency for the treatment of moderate to severe UC.Many clinical studies on tofacitinib in the treatment of UC have been carried out abroad,but there is no relevant report on its use in UC in China.This paper summarizes the relevant research advances of tofacitinib in the treatment of UC from its mechanism,clinical application and safety.The results show that tefatinib mainly treats UC by inhibiting the expression of JAK and proinflammatory factors,regulating the overexpressed signaling transducers and activators of transcription,and repairing the intestinal mucosal barrier.Tofacitinib has good clinical efficacy,but safety studies have shown that the risks of herpes zoster and thrombosis should not be ignored,and the drug should be used with caution in pregnant,children,adolescents,and elderly patients.The efficacy and safety of tofacitinib in Chinese population should be further studied in the future,since it has not been used in UC patients in China.
作者
吴澎泞
熊帅
杨婉卿
陈敏
WU Pengning;XIONG Shuai;YANG Wanqing;CHEN Min(School of Clinical Medicine,the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610075,China;Dept.of Anorectal Disease,the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610075,China)
出处
《中国药房》
CAS
北大核心
2022年第18期2299-2304,共6页
China Pharmacy
基金
国家自然科学基金资助项目(No.81774321)
科研能力提升“百人计划”项目(No.20-B05)。
关键词
托法替尼
溃疡性结肠炎
机制
临床研究
tofacitinib
ulcerative colitis
mechanism
clinical research
